Overview

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Status:
Terminated

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.

Phase:

Phase 3

Details

Lead Sponsor:

Bausch & Lomb Incorporated

Treatments:

7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Besifloxacin
Fluoroquinolones